Novo Nordisk is facing an investor lawsuit alleging the company made false statements about competition from personalized compounded drugs when estimating 2025 sales growth for its GLP-1 diabetes and obesity treatments, Ozempic and Wegovy. The lawsuit claims Novo’s projections underestimated the impact of this competition, leading to a significant drop in its share price after the company reduced its revenue estimates in May.
Source: https://www.fiercepharma.com/pharma/lawsuit-charges-novo-nordisk-underestimating-impact-competition-compounded-drugs